RxDoctor Payments Data

Serena Hu, MD

Orthopaedic Surgery of the Spine · Stanford, CANPI 1144274747

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $639,840 of the $738,063 with a category attached, or 86.7%. Globus Medical accounts for 88.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $640,772 and has fallen 91.4% since, to $55,081 in 2025.

$738,063in general payments, 2019–2025

Across 180 payments — averaging $4100.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$650K
  • Medtronic$77K
  • Highridge Medical LLC$4K
  • Mirus, LLC$2K
  • Alphatec Spine, Inc$1K
  • Si-bone, Inc.$995
  • plus $3K from 15 others

What the payments were for

  • Royalty or licence$639,84087%
  • Consulting fees$7,8751%
  • Speaking & faculty fees$63,1409%
  • Travel & lodging$13,5412%
  • Food & beverage$13,6672%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$738,063 in reported general payments places this provider in the 85th percentile of 288 orthopaedic surgery of the spine providers in California.

See all orthopaedic surgery of the spine providers in California

Medicare billing

Part B allowed, 2024
$363,146
Medicare patients
366
Services billed
1,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib12$140

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery of the spine in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →